Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Portola Pharmaceuticals (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“2017 was a year of significant achievement for Portola, highlighted by the FDA approval of our first medicine, Bevyxxa, and the regulatory application for FDA approval of our breakthrough-designated Factor Xa-inhibitor antidote, AndexXa,” said Bill Lis, chief executive officer of Portola. “We are pleased with the early indicators of the U.S. commercial launch of Bevyxxa, which began in January, and the potential to have a major public health impact on millions of patients in the U.S. and beyond. We also are rapidly approaching the FDA action date for AndexXa, which, if approved, would position Portola with two first-in-class medicines in the field of thrombosis. In the meantime, we are working with European regulatory authorities on the path forward for both medicines and are continuing to advance our dual, oral Syk/JAK inhibitor, cerdulatinib, for hematologic cancers.”

Click here to read the full press release.